The injectable tracer, Flyrcado, could help doctors flag deadly coronary artery disease in patients during imaging tests.

Using patient-derived tumor organoids, researchers have identified which therapies may be most effective for individual sarcoma patients.

Ozempic maker Novo Nordisk says its highly anticipated experimental weight-loss pill Amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.

and risks of drugs in large populations. Moran’s team at McLean Hospital in Belmont, MA, did research that looked at emergency room admissions and found that patients prescribed amphetamines ...

When asked about the disadvantages drug developers faced in developing these therapies, the limitation that more than half of respondents (53 percent) noted was biomarker identification and predicting ...

Drug rash refers to skin reactions as a side effect of certain medications. These rashes can vary from mild to severe and may appear as red spots, hives, or peeling skin. Common drugs that cause such ...

FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...

Daily Pill Helps People Lose Weight, Combines GLP-1 With Other Drug By Dennis Thompson HealthDay Reporter WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- An experimental weight-loss pill appears to ...

A daily pill can lead to faster weight loss in three months than Wegovy, a study has found. Early trials of amycretin showed it helped patients lose an average 13 per cent of their body weight in ...

The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks ...

It's robust and reliable, and it helps us accurately determine which pathways are malfunctioning in cancer without bias, enabling more precise drug identification." The research teams used PET to ...